Evidence map›Paper›PMID 31701475›Full record

ArticleMolecular biology reports2020

Correlation of MLH1 polymorphisms, survival statistics, in silico assessment and gene downregulation with clinical outcomes among breast cancer cases.

Saima Shakil Malik, Ayisha Zia, Sumaira Mubarik, Nosheen Masood, Sajid Rashid, Alice Sherrard, Muhammad Bilal Khan, Muhammad Tahir Khadim

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Genetic Variation ofInternational journal of dentistry · 2026
    Article
  2. Article
  3. Article
  4. Molecular Basis of Breast Tumor Heterogeneity.Advances in experimental medicine and biology · 2025
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Saima Shakil MalikFatima Jinnah Women University, The Mall Rawalpindi, Rawalpindi, Pakistan. saimamalik25@yahoo.com.ORCID http://orcid.org/0000-0001-6465-9339
Ayisha ZiaNational Centre for Bioinformatics, Quaid-i-Azam University, Islamabad, Pakistan.
Sumaira MubarikDepartment of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.
Nosheen MasoodFatima Jinnah Women University, The Mall Rawalpindi, Rawalpindi, Pakistan.
Sajid RashidNational Centre for Bioinformatics, Quaid-i-Azam University, Islamabad, Pakistan.
Alice SherrardDepartment of Cellular and Molecular Medicine, School of Life Sciences, Bristol University, Bristol, UK.
Muhammad Bilal KhanArmed Forces Institute of Pathology, Rawalpindi, Pakistan.
Muhammad Tahir KhadimArmed Forces Institute of Pathology, Rawalpindi, Pakistan.
Armed Forces Institute of Pathology · PKQuaid-i-Azam University · PKFatima Jinnah Women University · PKUniversity of Bristol · GBWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the role of MLH1 polymorphisms, respective protein structure prediction, survival analysis, related clinicopathological details and MLH1 expression in breast cancer (BC). Genotyping of selected SNPs in BC patients (493) and age matched controls (387) were performed by Tetra-ARMS PCR. Gene expression among breast tumors (127) and adjacent control tissues were analysed using reverse transcriptase PCR (RT-PCR) and immunohistochemistry. Statistical analysis was performed by SPSS and MedCalc. Conditional logistic regression analysis was applied to compute the odds ratio and confidence interval. Phyre2 and I-TASSER were used to generate MLH1 protein structures and verified by a variety of computational tools. Genotyping illustrated that MLH1 polymorphisms (rs63749795 and rs63749820) were significantly associated (P ≤ 0.05) with risk of developing BC. Down regulation of MLH1 gene expression/loss of the MLH1 protein (OR 12; CI 2.8-53.1) was observed in BC cases, illustrating its potential role in disease development. Moreover, loss of the MLH1 protein was found to be associated with higher grade cancer (P = 0.02) and lymph node positivity (P = 0.03), highlighting its essential role, as a component of the mismatch repair (MMR) machinery. Bioinformatics analysis confirmed that nonsense mutations produce a truncated MLH1 protein, causing a reduction in MMR efficiency. No association between MLH1 polymorphisms and overall and progression free survival statistics was observed among BC cases, possibly due to short follow-up study. Results at DNA, RNA and protein levels, along with in silico analysis, highlights the potential role of MLH1 in DNA repair mechanisms, within BC. Therefore, it was concluded that MLH1 may contribute towards BC development and progression.

Indexed as

Breast NeoplasmsMutL Protein Homolog 1AdultBreastDNA Mutational AnalysisDown-RegulationFemaleHumansMiddle AgedPolymorphism, Single NucleotideMLH1 protein, humanMutL Protein Homolog 1ARMS PCRBreast cancerExpressionMLH1PolymorphismsSurvival analysis

Identifiers

PMID31701475
OpenAlexW2986805761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.